Key result
Circulating collagen type I fragments, such as PICP and CITP, show potential as biomarkers for assessing cardiac fibrosis and predicting cardiovascular outcomes, despite challenges with assay standardization.
Why the study?
Biomarkers of collagen type I have been investigated in CVD for decades, but the evidence for clinical use remains inconclusive.
Do circulating collagen type I fragments serve as specific biomarkers of cardiovascular outcome risk in patients with cardiovascular diseases?
Do circulating collagen type I fragments serve as specific biomarkers of cardiovascular outcome risk in patients with cardiovascular diseases?
Circulating collagen type I fragments hold promise as biomarkers for assessing cardiac fibrosis and cardiovascular risk, but further multivariable approaches are needed to overcome current clinical barriers.
COL1 biomarkers remain inconclusive for CVD use; leaves open multivariable validation to address barriers.
• Collagen type I is overly deposited in fibrotic diseases, impacting organ structure and function. • Biomarkers of collagen type I have been investigated in cardiovascular disease for decades, but the evidence for clinical use remains inconclusive. • There are multiple mechanistic and clinical barriers that could influence consistency in cardiovascular indications. • Improvement of collagen type I biomarkers could be achieved through a multivariable approach. Collagen type I (COL1) is the most abundant protein in the human body and is a main component in the extracellular matrix. The COL1 structure vastly influences normal tissue homeostasis and changes in the matrix drive progression in multiple diseases. Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity in many Western countries; alterations in the extracellular matrix turnover processes, including COL1, are known to influence the pathophysiological processes leading to CVD outcome. Peptides reflecting COL1 formation and degradation have been established and explored for over two decades in CVD. This review aims to combine and assess the evidence for using COL1-derived circulating peptides as biomarkers in CVD. Secondly, the review identifies existing pitfalls, and evaluates future opportunities for improving the technical characteristics and performance of the biomarkers for implementation in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) conducted a review in Cardiovascular diseases. Circulating collagen type I fragments was evaluated. Circulating collagen type I fragments, such as PICP and CITP, show potential as biomarkers for assessing cardiac fibrosis and predicting cardiovascular outcomes, despite challenges with assay standardization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: